Full-Time

Senior Team Lead

Updated on 9/3/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Bengaluru, Karnataka, India

Hybrid

Hybrid work arrangement in Bangalore, India.

MBA

Category
Accounting (1)
Required Skills
SAP Products
Excel/Numbers/Sheets

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • CA, ACA, ICWA, CPA, CMA or any finance/accounting professional qualification is mandatory
  • MBA and/or other financial certifications is preferred
  • At least 7 - 10 years of professional experience is required
  • At least 2-3 years of Management / Supervisory experience is required
  • Strong interpersonal skills and the ability to interact with employees at all levels
  • Ability to frame clear & concise communication across all relevant stakeholders
  • Be open to new ideas, rapid change and embracing new technologies
  • Proficient in ERP systems (SAP preferred) and MS Office in particular Excel
Responsibilities
  • Be compliant with applicable laws and regulations, and follow guidelines in the J&J Credo
  • Maintain Operational Excellence
  • Responsible for executing accounting and daily operations for Account to Report (A2R) areas.
  • Timely closing & execution of financial periods as per closing calendar and in accordance with SLA commitments, fully observing Compliance, Internal Audit & SOX requirements.
  • Accountable for completeness, accuracy and validity of the actuals reported within process/entity scope.
  • Driving deep expertise, ensuring team are fully knowledgeable of the Worldwide Procedures and compliance requirements for respective areas.
  • Support auditors and legal authorities with the execution of required activities.
  • Understand, adhere, and execute per worldwide policies and procedures. Identify compliance risks and recommend solutions to remediate / prevent breach.
  • Ensure strong internal controls are in place, to achieve “adequate” internal and external audit ratings.
  • Attract, develop, and retain a highly competent, high-performing, motivated and diverse Credo-based team.
  • Develop succession plans for and support career development of the team.
  • Ensure effective performance management within team.
  • Lead a team of Analysts.
  • Execute global Strategy & Solutions in line with taxonomy.
  • Internally recruit, mentor, and drive the individual Process SMEs to ensure cross sector, cross region, and cross process alignment, ensuring good documentation is maintained and consistency of a global approach.
  • If assigned a role of Operational Key Contact (OKC) then candidates will be the key liaison point within their Process for a defined Region & Sector with BUF and CFMs, answering queries, coordinating with SMEs/analysts on process and operational matters, resolving issues and updating partners on close status.
  • If assigned a role of Subject Matter Expert (SME) then candidates will be responsible to ensure cross sector, cross region, and cross process alignment, ensuring good documentation is maintained and consistency of a global approach.
  • Generate ideas, fosters, and implements continuous improvement mindset, identifying and pursuing process efficiency opportunities.
  • Influence and Execute process improvements, generating ideas and implementing in line with global standards.
Desired Qualifications
  • Experience in a Global Account to Report function of a multinational company
  • Ability to handle ambiguity and fluid situations, demonstrating a pragmatic approach
  • Successfully manage multiple priorities, be very organized and work efficiently to tight deadlines
  • Solid US GAAP accounting knowledge
  • Digital/ intelligent automation capabilities
  • Fluent English, other language skills desirable

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.